Online inquiry

IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7477MR)

This product GTTS-WQ7477MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TGFB1&TGFB2&TGFB3 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000660.7; NM_001135599.4; NM_001329938.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7040; 7042; 7043
UniProt ID P01137; P61812; P10600
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7477MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4332MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ12545MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ1359MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-874
GTTS-WQ14353MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ5790MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ14925MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ3165MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ8205MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA hLIV22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW